EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 664 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Alex Trebek Thanks Fans In “Mind-Boggling” Cancer Update. May 31, 2019 Combination of Temozolomide and Capecitabine Associated with Improved PFS Compared to... October 24, 2022 Doxorubicin and Trabectedin Combination Improves Survival Among Patients with Metastatic or... September 13, 2024 Tattoo Ink May Show Up as Suspicious Spots in Lymph Nodes... July 9, 2021 Load more HOT NEWS Substantial Clinical Activity of Teclistamab in Patients with Heavily Pretreated Relapsed... Combining existing drugs improves prostate cancer survival Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... Higher Pregnancy Rates and No Impact on Prognosis with Embryo/Oocyte Cryopreservation...
